NCT01131039

Safety and Efficacy Study of Gemcitabine Plus Bevacizumab in Patients With Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer

A Phase II Trial of Gemcitabine Plus Bevacizumab in Patients With Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer

• Status: Withdrawn
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Emory University · Academic / Other
• Sex: Female
• Age: 19 Years
• Healthy volunteers: Not accepted

Summary

The purpose of the study is to determine whether the administration of bevacizumab and gemcitabine given by IV infusion can prolong survival, delay tumor growth, and/or shrink tumors in patients with ovarian cancer, primary peritoneal, or fallopian tube cancer.

Conditions

• Fallopian Tube Neoplasms
• Ovarian Cancer
• Primary Peritoneal

Interventions

Type	Name	Description
DRUG	Gemcitabine/Bevacizumab	Gemcitabine: IV, days 1,8, and every 21 days Bevacizumab: IV, day 1 and every 21 days until disease progression

Timeline

• Start date: 2011-01-01
• Primary completion: 2011-09-01
• Completion: 2011-09-01
• First posted: 2010-05-26
• Last updated: 2013-12-20